Search

Your search keyword '"Spitaleri, D."' showing total 285 results

Search Constraints

Start Over You searched for: Author "Spitaleri, D." Remove constraint Author: "Spitaleri, D."
285 results on '"Spitaleri, D."'

Search Results

1. Do patients’ and referral centers’ characteristics influence multiple sclerosis phenotypes? Results from the Italian multiple sclerosis and related disorders register

2. Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis

3. Machine-learning-based prediction of disability progression in multiple sclerosis: An observational, international, multi-center study

4. Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom

5. Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS Registry

6. Incidence and Long-term Functional Outcome of Neurologic Disorders in Hospitalized Patients with COVID-19 Infected with Pre-Omicron Variants

7. Data monitoring roadmap. The experience of the Italian Multiple Sclerosis and Related Disorders Register

8. Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients with Primary Progressive Multiple Sclerosis

9. The risk of secondary progressive multiple sclerosis is geographically determined but modifiable

10. Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis

11. Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis

12. Disability accrual in primary and secondary progressive multiple sclerosis

13. Comparative effectiveness in multiple sclerosis: A methodological comparison

14. Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis

15. Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry

16. Data monitoring roadmap. The experience of the Italian Multiple Sclerosis and Related Disorders Register

17. Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis

18. Diagnostic issues faced by a rare disease healthcare network during Covid-19 outbreak: data from the Campania Rare Disease Registry

20. Correction to: Prevalence and predictors of bowel dysfunction in a large multiple sclerosis outpatient population: an Italian multicenter study (Journal of Neurology, (2022), 269, 3, (1610-1617), 10.1007/s00415-021-10737-w)

21. Cost-Effectiveness Analysis of Cannabinoid Oromucosal Spray Use for the Management of Spasticity in Subjects with Multiple Sclerosis

22. Real-World Comparative Effectiveness and Persistence of Cladribine Tablets and Other Oral Disease-Modifying Treatments for Multiple Sclerosis from GLIMPSE: Results from the MSBase Registry

23. Cost-Effectiveness Analysis of Cannabinoid Oromucosal Spray Use for the Management of Spasticity in Subjects with Multiple Sclerosis

24. Confirmed disability progression as a marker of permanent disability in multiple sclerosis.

25. Confirmed disability progression as a marker of permanent disability in multiple sclerosis

26. Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis

27. Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS

28. Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: results from MSBase registry

29. Do patients' and referral centers' characteristics influence multiple sclerosis phenotypes? Results from the Italian multiple sclerosis and related disorders register

30. Impact of methodological choices in comparative effectiveness studies:application in natalizumab versus fingolimod comparison among patients with multiple sclerosis

31. Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression (vol 208, 106180, 2021)

32. Long-term outcomes in patients presenting with optic neuritis: analyses of the MSBase registry

33. Early predictors of disability in paediatric multiple sclerosis: evidence from a multi-national cohort

34. The Italian multiple sclerosis register

35. Preliminary results of the FASM study, an on-going italian active pharmacovigilance project

36. Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years

37. Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis.

38. Comparison of the effectiveness of ocrelizumab vs interferons, fingolimod and natalizumab on relapses in relapsing-remitting multiple sclerosis.

39. Disability accrual in primary-progressive & secondaryprogressive multiple sclerosis.

40. Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression

41. The effectiveness of natalizumab vs fingolimod-A comparison of international registry studies

42. Pregnancy in a modern day multiple sclerosis cohort: predictors of postpartum relapse and disability progression

43. Pregnancy in a modern day multiple sclerosis cohort: predictors of relapse during pregnancy

44. of Therapeutic Lag in Relapsing Multiple Sclerosis

45. Effect of disease modifying therapy on disability in Relapsing-Remitting multiple sclerosis over 15 Years

46. Predicting long-term sustained disability progression in multiple sclerosis.

47. Delay from treatment start to full effect of immunotherapies for multiple sclerosis

49. Comparative effectiveness of natalizumab and fingolimod in different subgroups of patients with relapsing-remitting multiple sclerosis

50. Therapeutic lag in relapsing multiple sclerosis

Catalog

Books, media, physical & digital resources